Abstract P2-01-12: Development of prediction model for omission of sentinel lymph node biopsy in T1 breast cancer
CONCLUSIONSThese mature data with long FU suggest that the outcome for a large cohort of unselected Pts with HER2-normal HR+ ESBC (regardless of nodal status) and for TN/N− ESBrCa treated with nonAReg TC is excellent. However, N+TN ESBrCa in this setting remains a significant clinical challenge.Citation Format: Cho JN, Song EJ, Lee MH, Jung S-Y, Lee S, Kang H-S, Sim SH, Park IH, Lee KS, Kim YJ, Kim S-K, Kwon Y, Nam B-H, Lee ES. Development of prediction model for omission of sentinel lymph node biopsy in T1 breast cancer [abstract]. In: Proceedings of the Thirty-Ninth Annual CTRC-AACR San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-01-12.
Source: Cancer Research - Category: Cancer & Oncology Authors: JN Cho, EJ Song, MH Lee, S-Y Jung, S Lee, H-S Kang, SH Sim, IH Park, KS Lee, YJ Kim, S-K Kim, Y Kwon, B-H Nam, ES Lee Tags: Poster Session Abstracts Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Cardiology | Clinical Trials | Congestive Heart Failure | Databases & Libraries | Docetaxel | Heart | Heart Failure | HER2 | Hormonal Therapy | Hormones | Taxotere